Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
4 hours ago
- #Clinical Trial
- #CAR-T Therapy
- #Multiple Myeloma
- Phase II study evaluates BCMA CAR-T therapy in newly diagnosed multiple myeloma (NDMM) patients ineligible for autologous stem-cell transplantation (ASCT).
- Primary endpoint: Minimal residual disease (MRD) negativity rate at Month three post-infusion was 100% (36 of 36 patients).
- Complete response rate (CRR) increased from 33.3% pre-infusion to 94.4% at last follow-up.
- Common grade 3-4 adverse events included transient cytopenia (lymphopenia, neutropenia, leukopenia).
- Cytokine release syndrome occurred in 52.8% of patients, all grade 1-2.
- No deaths or disease progressions were reported by the cutoff date.
- Findings suggest BCMA CAR-T therapy as a potentially practice-changing frontline strategy for NDMM patients.